This handout is for multiple endocrine neoplasia type 1 (men1). Your care team identified this based on: first-degree relative with men1 / known germline men1 mutation — cascade screening (thakker jcem 2012).
Other reasons your team may use this plan: primary hyperparathyroidism, especially age <40 or multiglandular disease (thakker jcem 2012); two or more of parathyroid / pancreatic-duodenal net / pituitary tumors (thakker jcem 2012 diagnostic criteria); recurrent / refractory peptic ulcer or secretory diarrhea — zollinger-ellison from gastrinoma (thakker jcem 2012).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| subtotal or total parathyroidectomy with cryopreservation | — | surgical | — | Thakker JCEM 2012 — MEN1 pHPT is multiglandular; less-than-subtotal resection has high recurrence. Subtotal (3.5-gland) or total parathyroidectomy with transcervical thymectomy + parathyroid tissue cryopreservation; balance recurrence vs permanent hypoparathyroidism |
| cinacalcet | 30 mg | PO | daily, titrate to BID | Thakker JCEM 2012 — lowers calcium when surgery deferred/declined or for persistent disease; does not treat the underlying multiglandular hyperplasia |
| cholecalciferol | 1000-2000 IU | PO | daily | Thakker JCEM 2012 — cautious repletion of concomitant vitamin D deficiency optimizes interpretation and bone health |
Plan: MEN1 organ-directed ladder (parathyroid → gastrinoma → insulinoma → pituitary → carcinoid surveillance/resection)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Cascade genetic testing + counseling for at-risk first-degree relatives (offer from ~5-10 y of age depending on earliest familial tumor), patient education, smoking cessation (thymic risk), pregnancy planning, and lifelong MEN1-center follow-up (Thakker JCEM 2012)
Guideline: 2012 Endocrine Society MEN1 Clinical Practice Guideline (Thakker); 2021-2025 MEN1 surveillance updates